Benzinga | Nov 15, 2021 11:10AM EST

Kala Pharmaceuticals Q3 EPS $(0.43), Inline, Sales $3.10M Miss $5.16M Estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(0.43) per share which met the analyst consensus estimate. This is a 14 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $3.10 million which missed the analyst consensus estimate of $5.16 million by 39.92 percent. This is a 39.64 percent increase over sales of $2.22 million the same period last year.